Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin Plus Rituximab in PTLD
NCT06040320Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of polatuzumab vedotin in Post-Transplant Lymphoproliferative Disorder (PTLD) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Frequency and severity of treatment-related adverse events, Number of dose-limiting toxicities and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT06040320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040320.